-
Mashup Score: 0Rituximab Maintenance ‘Benefits’ Older Patients with MCL Who Do Not Undergo AHSCT | Blood Cancers Today - 2 year(s) ago
Rituximab maintenance had “significant benefits” for survival and disease control in older patients with MCL who did not receive AHSCT, despite the shift in first-line induction.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Low Rates of Chemoimmunotherapy for Patients with DLBCL in Nursing Homes | Blood Cancers Today - 2 year(s) ago
Older patients with DLBCL who received nursing home care were less likely to receive chemoimmunotherapy and had poorer survival than those who did not reside in a nursing home.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Older patients with DLBCL who received nursing home care were less likely to receive chemoimmunotherapy and had poorer OS than those who did not reside in a nursing home, according to a study by @DiMengyang of @YaleMed and colleagues. https://t.co/kIWhCULKaZ https://t.co/9ajXJxDZix
-
-
Mashup Score: 0Rituximab Maintenance ‘Benefits’ Older Patients with MCL Who Do Not Undergo AHSCT | Blood Cancers Today - 2 year(s) ago
Rituximab maintenance had “significant benefits” for survival and disease control in older patients with MCL who did not receive AHSCT, despite the shift in first-line induction.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rituximab maintenance had “significant benefits” for survival and disease control in older patients with MCL who did not receive AHSCT, according to a recent population-based real-world analysis by @DiMengyang of @YaleMed and @YaleCOPPER and colleagues. https://t.co/TiELXFb1Ha https://t.co/8V6ZidRxgX
-
-
Mashup Score: 1Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL - 2 year(s) ago
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Source: HMP Global Learning NetworkCategories: Hem/Oncs, Latest HeadlinesTweet-
Our amazing fellow @YaleCancer @DiMengyang & #Lymphsm & outcomes research rising star talking about her oral #ASH22 presentation on Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL https://t.co/f06Iy3QLVd
-
-
Mashup Score: 5Global Risk Indicator and Therapy for Older Patients With Diffuse Large B-Cell Lymphoma: A Population-Based Study - 3 year(s) ago
PURPOSE: To examine the impact of global risk, a measure comprising age, comorbidities, function, and cognitive statuses, on treatment selection and outcomes among older home care recipients with diffuse large B-cell lymphoma. METHODS: From SEER-Medicare, we selected home care recipients diagnosed with diffuse large B-cell lymphoma in 2011-2015, who had pretreatment Outcome and Assessment…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
An OASIS-based measure with age, comorbidities, function & cognitive status can assess global risk for older pts with Diffuse Large B-Cell Lymphoma & may improve patient selection for curative #DLBCL treatment #JCOOP #lymsm #gerionc @DiMengYang https://t.co/8ejjX7dnAP https://t.co/KkLdZRcojA
-
-
Mashup Score: 1Mengyang Di and Scott Huntington on Anti-Infective Prophylaxis - 3 year(s) ago
With lack of evidence and guidance, use was low, study found
Source: www.medpagetoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DiMengyang: Thanks @medpagetoday for featuring our study! @sfhYALE https://t.co/VrVvxXpJ0k https://t.co/2JPYnVeJrd
-
-
Mashup Score: 062nd ASH Annual Meeting and Exposition - 4 year(s) ago
The ASH annual meeting is the world’s most comprehensive hematology event of the year for an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates on the most critical topics in hematology.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Congrats Dr. @DiMengyang - great companion to your original work coming up tomorrow! https://t.co/sDoMU90osC #lymsm https://t.co/9EMN0uUsYF
-
ICYMI: Rituximab maintenance had “significant benefits” for survival and disease control in older patients with MCL who did not receive AHSCT, according to a recent analysis by @DiMengyang of @YaleMed/@YaleCOPPER and colleagues. https://t.co/8OvBJOym6I https://t.co/8EMibY5FlQ